COVID-19 vaccines have prevented 7.2 million infections and 27,000 deaths in England alone

Latest modelling analysis from Public Health England (PHE) and the University of Cambridge’s MRC Biostatistics Unit suggests that the coronavirus (COVID-19) vaccination programme has so far prevented an estimated 7.2 million infections and 27,000 deaths in England alone.

This is the first analysis giving an estimated number of vaccine-prevented infections, providing further evidence of the staggering impact of the vaccination programme so far.

PHE Head of Immunisation Dr Mary Ramsay said: "These findings remind us once again why getting both doses of your vaccine is the most important thing you can do to stop the spread of this terrible disease.

"As well as preventing the deaths of tens of thousands from COVID-19, for the first time we can now appreciate the huge impact that the vaccines have had on stopping people getting infected, and therefore passing the virus on to others."

The results were produced using the PHE and Cambridge real-time pandemic surveillance model, looking at the direct and indirect impact of the COVID-19 vaccination programme on infections and mortality.

The total was calculated by comparing the estimated impact of vaccination on infection and mortality against a worst-case scenario where no vaccines were in place to reduce infections and mortality.

Dr Paul Birrell, Senior Research Associate at the MRC Biostatistics Unit, University of Cambridge and Senior Principal Modeller at PHE, said: "The number of infections and deaths saved by the vaccination programme is not only astoundingly high, but continues to grow exponentially as the vaccination programme continues.

"In practice, this analysis highlights that the vaccination programme has given us a path back towards a normal life that wouldn’t otherwise have been possible. This is why it’s so important that we all get 2 doses of the vaccine as soon as we can."

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...